Pfizer's Paxlovid gets March FDA advisory meeting to discuss full approval
Pfizer’s antiviral drug for Covid-19 is looking to inch closer to full FDA approval, with an agency advisory committee scheduled for March.
The meeting is going to be held on March 16 from 9 a.m. to 5 p.m. EST, according to a document in the federal register from the US Department of Health and Human Services. The meeting will focus on whether Paxlovid should be approved to treat mild-to-moderate Covid-19 in adults who are at high risk for the virus’ progression to a severe case which can lead to hospitalization or death.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,900+ biopharma pros reading Endpoints daily — and it's free.